Business
Voyageur Pharmaceuticals Ltd. Announces DSU Grants
(TheNewswire) Calgary, Alberta - TheNewswire - July 13, 2023 - Voyageur Pharmac...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Ltd. Announces DSU Grants\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Alberta -\n \n \n TheNewswire -\n \n \n July 13, 2023 -\n \n \n Voyageur Pharmaceuticals Ltd.\n \n \n (TSX.V:VM)\n \n \n (USA:VYYRF)\n \n \n (the \"\n \n \n Company\n \n \n \" or\n\"\n \n \n Voyageur\n \n \n \") announces that on July 10, 2023, it issued 383,360\nDeferred Share Units (\"DSUs\") to directors of the Company\npursuant to its fixed 10% equity incentive compensation plan (the\n\"Plan\").  Each DSU represents a right of the holder to\nreceive one common share (\"Common Share\") of the Company\neffective as of the date that the holder ceases service as a director\nof the Company. The DSUs are used to compensate directors of the\nCorporation for their annual retainers and are issued quarterly using\na deemed value that is equal to the weighted average share price\nduring that quarter. The DSUs do not have an exercise price but have a\nstarting value equal to approximately $.0815 per DSU, based on the\nweighted average share price for the quarter ended June 30, 2023. The\nDSUs are subject to the terms of the Plan and the policies of the TSX\nVenture Exchange (the \"Exchange\").  The DSUs and any Common\nShares issued pursuant to the exercise of the DSUs are subject to a\nfour month hold in accordance with the policies of the\nExchange.\n \n \n \n \n About Voyageur Pharmaceuticals\nLtd.\n \n \n \n \n Voyageur, a Canadian public company trading under the\nsymbol VM on the TSXV, is in development of barium, iodine and carbon\nActive Pharmaceutical Ingredients (API) and high-performance,\ncost-effective imaging contrast agents. With a strategic focus on\nvertically integrating the barium, iodine and carbon contrast imaging\nmarket, Voyageur aims to become a key player by producing its own\nbarium, iodine, and fullerene minerals.\n \n \n \n \n Our business plan is set to generate cash flow by\npartnering with established third-party GMP pharmaceutical\nmanufacturers in Canada, ensuring the validation of our products by\nregulatory agencies worldwide. As we solidify our presence in the\nmarket, we will transition into a high-margin domestic manufacturer of\nradiology drugs, further expanding our revenue streams.\n \n \n \n \n Voyageur is commi...